ZURICH (Thomson Financial) - Newron Pharmaceuticals SpA has received US FDA approval for an investigational new drug application (IND) to conduct clinical trials with ralfinamide for treatment of chronic pain, the company said in a statement.
[News Source]
[News Source]
Blogosphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg


